We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

561 hedge funds and large institutions have $26B invested in Alexion Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 220 increasing their positions, 204 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 84 | Existing positions closed: 61

2% more funds holding

Funds holding: 548 → 561 (+13)

8% more repeat investments, than reductions

Existing positions increased: 220 | Existing positions reduced: 204

2% more call options, than puts

Call options by funds: $261M | Put options by funds: $257M

3% less capital invested

Capital invested by funds: $26.9B → $26B (-$932M)

29% less funds holding in top 10

Funds holding in top 10: 24 → 17 (-7)

Holders
561
Holders Change
+13
Holders Change %
+2.37%
% of All Funds
13.97%
Holding in Top 10
17
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-29.17%
% of All Funds
0.42%
New
84
Increased
220
Reduced
204
Closed
61
Calls
$261M
Puts
$257M
Net Calls
+$4.33M
Net Calls Change
+$22.1M

Top Buyers

1
BlackRock
BlackRock
New York
+$2.32B
2
JP Morgan Chase
JP Morgan Chase
New York
+$175M
3
Jennison Associates
Jennison Associates
New York
+$174M
4
Norges Bank
Norges Bank
Norway
+$128M
5
PI
Putnam Investments
Massachusetts
+$122M

Top Sellers

1
Capital Research Global Investors
Capital Research Global Investors
California
-$922M
2
Winslow Capital Management
Winslow Capital Management
Minnesota
-$275M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$232M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$150M
5
WRF
Waddell & Reed Financial
Kansas
-$134M
Name Holding Trade Value Shares
Change 		Change in
Stake
HCMT
251
Highland Capital Management (Texas)
Texas
$2.89M -$4.44M -34,450 -59%
OPERF
252
Oregon Public Employees Retirement Fund
Oregon
$2.84M – – –
DnB Asset Management
253
DnB Asset Management
Norway
$2.84M +$271K +2,100 +10%
M&T Bank
254
M&T Bank
New York
$2.81M -$510K -3,955 -15%
RIM
255
Rainier Investment Management
Washington
$2.77M -$1.25M -9,705 -30%
NMERB
256
New Mexico Educational Retirement Board
New Mexico
$2.76M -$155K -1,200 -5%
SAM
257
Securian Asset Management
Minnesota
$2.74M +$1.29K +10 +0%
RFC
258
Regions Financial Corp
Alabama
$2.74M -$962K -7,461 -25%
OAM
259
Oppenheimer Asset Management
New York
$2.73M +$2.91M +22,561 New
NIPH
260
NN Investment Partners Holdings
Netherlands
$2.67M -$406K -3,147 -12%
Capstone Investment Advisors
261
Capstone Investment Advisors
New York
$2.62M +$2.79M +21,619 New
GAM
262
Gotham Asset Management
New York
$2.6M +$965K +7,484 +54%
PPCM
263
Pillar Pacific Capital Management
California
$2.57M +$160K +1,242 +6%
CAM
264
Capstone Asset Management
Texas
$2.56M -$79.9K -620 -3%
DBG
265
De Burlo Group
Massachusetts
$2.54M -$601K -4,664 -18%
P
266
Pitcairn
Pennsylvania
$2.48M -$1.06M -8,216 -29%
Jane Street
267
Jane Street
New York
$2.45M -$9.31M -72,251 -78%
TMAM
268
Tokio Marine Asset Management
Japan
$2.35M +$1.92M +14,911 +334%
Marshall Wace
269
Marshall Wace
United Kingdom
$2.31M -$10.2M -79,196 -81%
WBC
270
Westpac Banking Corp
Australia
$2.29M +$569K +4,413 +30%
SMDAM
271
Sumitomo Mitsui DS Asset Management
Japan
$2.29M +$238K +1,849 +11%
Group One Trading
272
Group One Trading
Illinois
$2.27M -$2.78M -21,526 -53%
OPPM
273
Opus Point Partners Management
New York
$2.27M -$809K -6,272 -25%
RIA
274
Regal Investment Advisors
Michigan
$2.27M -$362K -2,810 -13%
OI
275
Oakbrook Investments
Illinois
$2.23M +$1.06M +8,250 +81%
9 10
11
12 13

ALXN Hedge Fund Activity: Q1 2017 in Review

561 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q1 2017, worth a combined $26B — down 3.5% from $26.9B a quarter earlier.

Buyers outnumbered sellers: 84 funds opened new ALXN positions and 61 closed out — a net gain of 23 holders — while 220 added to existing stakes and 204 trimmed.

The largest buyer was BlackRock, adding an estimated $2.32B. The largest seller was Capital Research Global Investors, cutting an estimated $922M.

  • 561 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q1 2017, up from 548 in Q4 2016.
  • Funds reported $26B of Alexion Pharmaceuticals stock for Q1 2017, down 3.5% quarter-over-quarter.
  • 84 funds opened new Alexion Pharmaceuticals positions in Q1 2017 and 61 closed out, a net change of +23 holders.
  • The largest Alexion Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $2.32B added.
  • The largest Alexion Pharmaceuticals seller in Q1 2017 was Capital Research Global Investors, an estimated $922M sold.

Based on aggregated 13F filings for Q1 2017.